Peptides Similar to Afamelanotide

Melanocortin Peptide Family#

Afamelanotide is part of the melanocortin receptor agonist family. Understanding the differences between these peptides is important for clinical context and safety.

Afamelanotide vs. Melanotan I#

Afamelanotide and Melanotan I are the same peptide sequence ([Nle4, D-Phe7]-alpha-MSH). The difference is in formulation and regulatory status:

Melanotan II#

Melanotan II is a cyclic heptapeptide (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2) with broader melanocortin receptor activity. Key differences from afamelanotide:

• Multi-receptor activity: Activates MC1R, MC3R, MC4R, and MC5R
• Additional effects: Causes appetite suppression (MC4R), sexual arousal (MC4R), and GI effects (MC3R)
• Not approved: Melanotan II is not approved by any regulatory authority
• Safety concerns: Broader receptor activation increases the risk of unwanted effects

Alpha-MSH (Native Hormone)#

Native alpha-MSH is the endogenous tridecapeptide that afamelanotide was designed to mimic. Afamelanotide's two substitutions (Nle4, D-Phe7) make it 10-100x more potent and far more metabolically stable than the native hormone.

PT-141 (Bremelanotide)#

PT-141 is another melanocortin analog derived from Melanotan II, approved for hypoactive sexual desire disorder. While structurally related to afamelanotide through the melanocortin family, PT-141 acts primarily through MC4R for sexual function and has a completely different therapeutic indication.

Comparison Context#

Afamelanotide belongs to the Skin category of research peptides. Comparing Afamelanotide with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.

Detailed Comparisons#

The following peptides and compounds are most closely related to Afamelanotide in mechanism, indication, or therapeutic category:

Afamelanotide vs Melanotan II#

Similarity: High - Both are melanocortin receptor agonists that stimulate melanogenesis, but with different receptor selectivity profiles

Key Differences: Melanotan II is a cyclic heptapeptide that activates MC1R, MC3R, MC4R, and MC5R broadly. Afamelanotide is a linear tridecapeptide more selective for MC1R. Afamelanotide is FDA-approved while Melanotan II is not approved in any jurisdiction.

Advantages of Melanotan II: FDA-approved with extensive clinical trial data, more selective MC1R agonism with fewer off-target effects, sustained-release implant formulation, legitimate medical indication

Disadvantages of Melanotan II: Requires healthcare provider administration (implant procedure), only approved for EPP (very limited indication), extremely expensive, available only through REMS program

Researchers choosing between Afamelanotide and Melanotan II should consider the development stage, available evidence, and specific research objectives when making their selection.

Afamelanotide vs Melanotan I#

Similarity: Very high - Afamelanotide IS the pharmaceutical-grade version of Melanotan I (same peptide sequence)

Key Differences: Melanotan I refers to the unregulated research peptide version of the same NDP-MSH sequence. Afamelanotide is the approved pharmaceutical formulation in a controlled-release PLGA implant with quality-controlled manufacturing.

Advantages of Melanotan I: Pharmaceutical-grade purity and manufacturing, FDA/EMA-approved implant formulation, proven clinical efficacy and safety, legitimate medical use

Disadvantages of Melanotan I: Only available through REMS program, much more expensive than research- grade peptide, limited to EPP indication

Researchers choosing between Afamelanotide and Melanotan I should consider the development stage, available evidence, and specific research objectives when making their selection.

Related Reading#

• Afamelanotide overview and research guide
• Afamelanotide research evidence
• Afamelanotide dosing protocols